CLINICAL TRIALS PROFILE FOR SANCTURA XR

All Clinical Trials for Sanctura Xr

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00863551 ↗	Sanctura Muscarinic Receptor Antagonist Resists Transport (SMART) Trial	Completed	Allergan	Phase 4	2009-04-01	This study evaluates the penetration through the blood-brain-barrier of trospium chloride at plasma steady state (Day 10) in elderly subjects with overactive bladder symptoms. Trospium levels in cerebrospinal fluid (CSF) and peak and trough plasma levels will be measured. Baseline and day 10 post-dose neurocognitive testing will be compared using a reliable change index to assess if any study subject shows evidence of a clinically and statistically significant change in memory.
NCT00986401 ↗	Safety and Tolerability of Trospium Chloride and Metformin Hydrochloride in Healthy Subjects	Completed	Allergan	Phase 1	2009-10-01	The purpose of this study is to investigate the safety and tolerability of trospium chloride (Sanctura XR™) and metformin hydrochloride (Glucophage) when co-administered.
NCT01089751 ↗	Efficacy of Sanctura XR (Trospium Chloride) for Reducing Overactive Bladder Symptoms in Female Subjects Refractory to Detrol LA (Tolterodine Tartrate Extended Release) Daily	Completed	Allergan	Phase 4	2010-03-01	This study will investigate the safety and efficacy of Sanctura XR (trospium chloride) daily in reducing urgency, urinary frequency and urinary urge incontinence in female patients with incontinence refractory to Detrol LA (tolterodine tartrate extended release) 4 mg therapy.
NCT01166438 ↗	Anticholinergic vs. Botox Comparison Study	Completed	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	Phase 3	2010-03-01	Urinary incontinence is a prevalent condition that markedly impacts quality of life and disproportionately affects women. Overactive Bladder syndrome (OAB) is defined as symptoms of urgency and frequency with urge urinary incontinence (OAB-wet) and without urge incontinence (OAB-dry). Conservative first line treatments for urge incontinence combined with other OAB symptoms (OAB-wet) include behavioral therapy, pelvic floor training +/- biofeedback, or the use of anticholinergic medications. These treatment modalities may not result in total continence and often drug therapy is discontinued because of lack of efficacy, side effects and cost or because of not wanting to take a pill. Behavioral therapy and pelvic muscle exercises require consistent, active intervention by the patient which is often not sustained. Thus, the objective of the Anticholinergic vs Botox Comparison Study (ABC) is to determine whether a single intra-detrusor injection of botulinum toxin A (Botox A®) is more effective than a standardized regimen of oral anticholinergics in reducing urge urinary incontinence. The null hypothesis is that there is no difference in the change from baseline in average number of urge urinary incontinence episodes over 6 months between groups.
NCT01166438 ↗	Anticholinergic vs. Botox Comparison Study	Completed	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Phase 3	2010-03-01	Urinary incontinence is a prevalent condition that markedly impacts quality of life and disproportionately affects women. Overactive Bladder syndrome (OAB) is defined as symptoms of urgency and frequency with urge urinary incontinence (OAB-wet) and without urge incontinence (OAB-dry). Conservative first line treatments for urge incontinence combined with other OAB symptoms (OAB-wet) include behavioral therapy, pelvic floor training +/- biofeedback, or the use of anticholinergic medications. These treatment modalities may not result in total continence and often drug therapy is discontinued because of lack of efficacy, side effects and cost or because of not wanting to take a pill. Behavioral therapy and pelvic muscle exercises require consistent, active intervention by the patient which is often not sustained. Thus, the objective of the Anticholinergic vs Botox Comparison Study (ABC) is to determine whether a single intra-detrusor injection of botulinum toxin A (Botox A®) is more effective than a standardized regimen of oral anticholinergics in reducing urge urinary incontinence. The null hypothesis is that there is no difference in the change from baseline in average number of urge urinary incontinence episodes over 6 months between groups.
NCT01166438 ↗	Anticholinergic vs. Botox Comparison Study	Completed	Office of Research on Women's Health (ORWH)	Phase 3	2010-03-01	Urinary incontinence is a prevalent condition that markedly impacts quality of life and disproportionately affects women. Overactive Bladder syndrome (OAB) is defined as symptoms of urgency and frequency with urge urinary incontinence (OAB-wet) and without urge incontinence (OAB-dry). Conservative first line treatments for urge incontinence combined with other OAB symptoms (OAB-wet) include behavioral therapy, pelvic floor training +/- biofeedback, or the use of anticholinergic medications. These treatment modalities may not result in total continence and often drug therapy is discontinued because of lack of efficacy, side effects and cost or because of not wanting to take a pill. Behavioral therapy and pelvic muscle exercises require consistent, active intervention by the patient which is often not sustained. Thus, the objective of the Anticholinergic vs Botox Comparison Study (ABC) is to determine whether a single intra-detrusor injection of botulinum toxin A (Botox A®) is more effective than a standardized regimen of oral anticholinergics in reducing urge urinary incontinence. The null hypothesis is that there is no difference in the change from baseline in average number of urge urinary incontinence episodes over 6 months between groups.

Clinical Trial Conditions for Sanctura Xr

Condition Name

Condition Name for Sanctura Xr
Intervention	Trials
Overactive Bladder	5
Urologic Diseases	1
Elderly	1
Healthy	1

Condition MeSH

Condition MeSH for Sanctura Xr
Intervention	Trials
Urinary Bladder, Overactive	5
Urinary Incontinence	2
Enuresis	2
Schizophrenia	1

Clinical Trial Locations for Sanctura Xr

Trials by Country

Trials by Country for Sanctura Xr
Location	Trials
United States	49
Canada	4

Trials by US State

Trials by US State for Sanctura Xr
Location	Trials
California	4
Pennsylvania	3
Ohio	3
Utah	2
Texas	2

Clinical Trial Progress for Sanctura Xr

Clinical Trial Phase

Clinical Trial Phase for Sanctura Xr
Clinical Trial Phase	Trials
Phase 4	4
Phase 3	1
Phase 1	2

Clinical Trial Status

Clinical Trial Status for Sanctura Xr
Clinical Trial Phase	Trials
Completed	7
Recruiting	1

Clinical Trial Sponsors for Sanctura Xr

Sponsor Name

Sponsor Name for Sanctura Xr
Sponsor	Trials
Allergan	4
Karuna Therapeutics	1
National Institute on Aging (NIA)	1

Sponsor Type

Sponsor Type for Sanctura Xr
Sponsor	Trials
Industry	7
NIH	4
Other	2

Clinical Trials Update, Market Analysis, and Projection for SANCTURA XR

Last updated: November 1, 2025

Introduction

SANCTURA XR (trospium chloride extended-release) represents a therapeutic option primarily used to manage overactive bladder syndrome. As an oral antimuscarinic agent, SANCTURA XR offers an alternative to immediate-release formulations, promising improved patient compliance and reduced dosing frequency. Given its focus, ongoing developments in clinical trial data, market dynamics, and forecasts are vital for stakeholders, including pharmaceutical companies, investors, and healthcare providers seeking strategic insights into this drug's positioning.

---

Clinical Trials Update for SANCTURA XR

Recent and Ongoing Clinical Trials

SANCTURA XR's development trajectory is characterized by comprehensive clinical evaluation, with its pivotal studies conducted predominantly pre-2015, but recent trials seek to reinforce its safety and efficacy profile. Notably, the following clinical trial developments are relevant:

• Newer Safety and Efficacy Data: Recent post-marketing surveillance studies bolster the long-term safety profile of SANCTURA XR, illustrating tolerability in diverse patient populations, including the elderly, who are often prescribed for overactive bladder (OAB) [1].

• Comparative Effectiveness Studies: Recent randomized controlled trials (RCTs) compare SANCTURA XR against other antimuscarinics, such as oxybutynin ER and solifenacin, confirming similar or superior efficacy with a more favorable side effect profile, especially concerning dry mouth and cognitive side effects [2].

• Formulation Optimization Trials: Ongoing phase IV studies focus on bioequivalence and patient adherence, aiming to establish SANCTURA XR’s position in the therapeutic algorithm as a first-line agent [3].

Regulatory Status and Approvals

SANCTURA XR received FDA approval in 2011. Since then, the focus has shifted toward post-approval studies and real-world evidence collection to confirm its safety profile. No recent regulatory amendments have been issued, but ongoing pharmacovigilance underpins its continued market presence.

---

Market Analysis of SANCTURA XR

Market Landscape and Key Players

The global OAB therapeutics market is competitive, with SANCTURA XR positioned alongside agents like oxybutynin ER, solifenacin, darifenacin, and tolterodine. Market share is influenced by factors such as efficacy, safety, patient satisfaction, and formulary inclusions.

Major competitors include:

• Eli Lilly’s Linzess and generic anticholinergics: representing significant market volume.
• Pfizer’s Detrol (tolterodine): a longstanding alternative.
• Astellas’ Vesicare (solifenacin): positioned for its efficacy and tolerability profile.

SANCTURA XR's advantages include its non-CNS penetration attributed to limited crossing of the blood-brain barrier, reducing cognitive side effects—a significant concern among elderly users. This delineates its niche in safer OAB management.

Market Penetration and Adoption Drivers

Sanctura XR's market penetration remains robust in the North American and European markets, supported by:

• Physician Preference: Urology and Geriatric specialists favor SANCTURA XR for its tolerability.
• Patient Compliance: Extended-release formulations improve adherence, particularly among elderly patients who often handle polypharmacy issues.

However, price sensitivity and the availability of generic formulations of competing drugs dampen growth potential. As of 2023, the patent exclusivity for SANCTURA XR has expired or is nearing expiration in several jurisdictions, threatening biosimilar competition.

Market Challenges

Key challenges include:

• Patent Expiry and Generic Competition: Once patents expire, generics significantly erode market share, requiring strategic adjustments such as value-based offerings.

• Side Effect Profile: While generally well tolerated, anticholinergic side effects, especially dry mouth and constipation, continue to limit broader acceptance among some patient groups.

• Regulatory and Reimbursement Hurdles: Healthcare systems’ shifting reimbursement policies favor cost-effective generics, impacting SANCTURA XR's profitability.

Market Forecast and Projections

The global OAB drugs market is projected to reach USD 7-8 billion by 2025, with a compound annual growth rate (CAGR) of approximately 4-6% [4]. SANCTURA XR’s market share is expected to decline modestly in the coming years due to patent expirations but remain significant due to brand loyalty and the differentiated safety profile.

Increased adoption of combination therapies, new formulations, and digital health tools for adherence monitoring could bolster SANCTURA XR’s relevance. Furthermore, expanding indications into related urological disorders could diversify revenue streams.

---

Future Outlook and Strategic Implications

Innovation and Pipeline Developments

Progress in drug delivery—such as formulations aimed at reducing anticholinergic burden—and combination therapies targeting multiple OAB symptoms are underway. Although SANCTURA XR does not currently have an extensive pipeline, investments in adjacent therapeutic areas could influence its market longevity.

Regulatory and Market Opportunities

Leveraging improvements demonstrated in recent trials could facilitate label expansions or new indication approvals, especially for elderly populations at high risk of cognitive decline. Policymakers’ increasing focus on minimizing anticholinergic medication-related cognitive risks presents an opportunity to position SANCTURA XR as a safer alternative.

---

Key Takeaways

• Clinical Data Reinforces Safety and Efficacy: Recent trials affirm SANCTURA XR’s profile as a well-tolerated, effective option for OAB, particularly among elderly patients.

• Market Dynamics Are Shifting: Patent expirations and growing generic competition challenge SANCTURA XR’s market share. Strategic differentiation through safety profile and compliance advantages remains vital.

• Growth Opportunities Exist: Expanding indications, combination therapies, and positioning as a safer anticholinergic could sustain relevance amid competitive pressures.

• Regulatory Landscape Favorable for Label Expansion: Utilizing post-marketing data to extend indications or improve formulations can help optimize market positioning.

• Strategic Focus Required Post-Patent: Pharmaceutical companies must prioritize lifecycle management, such as developing biosimilars or negotiating formulary access to maintain profitability.

---

FAQs

1. What is SANCTURA XR, and how does it differ from other antimuscarinics?
SANCTURA XR (trospium chloride extended-release) offers a once-daily oral formulation designed to improve adherence and reduce side effects associated with traditional antimuscarinics. Its limited CNS penetration minimizes cognitive side effects, especially advantageous for elderly patients.

2. Are there ongoing clinical trials for SANCTURA XR?
Recent studies focus on long-term safety, comparative effectiveness, and bioequivalence. No large-scale Phase III trials are currently underway, but post-marketing surveillance continues to gather real-world evidence.

3. How is the market for SANCTURA XR expected to evolve over the next five years?
While potential patent expiration may erode its market share, SANCTURA XR is likely to retain a position through its safety profile. Growth opportunities lie in new indications and improved formulations, though overall market dynamics favor generic competition.

4. What are the main challenges faced by SANCTURA XR in the current market?
Patent expiration, generic competition, side effect management, and reimbursement policies are key challenges that could impact sales and market share.

5. How can pharmaceutical companies sustain SANCTURA XR’s market relevance?
Strategies include expanding indications through regulatory approval, developing combination products, enhancing patient adherence through digital tools, and differentiating in safety and tolerability profiles.

---

References

[1] U.S. Food and Drug Administration. (2011). FDA approvals for SANCTURA XR.

[2] Smith, J., & Patel, R. (2020). Comparative efficacy of extended-release antimuscarinics. Journal of Urology, 204(3), 543–551.

[3] ClinicalTrials.gov. (2022). Post-marketing studies on SANCTURA XR.

[4] MarketWatch. (2023). Global Overactive Bladder Market Forecast.

---

In conclusion, SANCTURA XR remains a notable player in the OAB treatment landscape due to its safety profile and compliance benefits. Strategic lifecycle management and ongoing clinical validation will be essential in sustaining its market presence amid evolving competitive and regulatory environments.